welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update
Solid Biosciences Inc. (Nasdaq: SLDB) today reported financial results for the first quarter ended March 31, 2019 and provided a business update.
“We have continued to advance our programs for Duchenne muscular dystrophy over the last few months, particularly our lead microdystrophin gene therapy candidate, SGT-001. Building on our findings from the preliminary Phase I/II clinical data that we announced in February, we initiated dosing at 2E14 vg/kg in the second cohort of patients,” said Ilan Ganot, Chief Executive Officer, President and Co-Founder of Solid Biosciences. “Now, we are working to progress as quickly as possible, and we look forward to providing additional data later this year.”
rareRelated
-
Development of a CRISPR-based gene therapy approach targeting the large exon 45-exon 55 mutation hotspot in DMD geneGene replacement and exon skipping thera...
-
New CRISPR Method Takes on Duchenne Muscular DystrophyThe advance of CRISPR gene editing techn...
-
Pfizer doses first patient using investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular...Pfizer Inc. has initiated a Phase 1b cli...
-
AAV-Based Gene Therapies for the Muscular DystrophiesMuscular dystrophy is a group of progres...
-
CRISPR/Cas9-Generated Mouse Model of Duchenne Muscular Dystrophy Recapitulating a Newly Identified Large 430 Kb Dele...Exon skipping is a promising strategy fo...
-
Upgrading the toolbox for Duchenne muscular dystrophy research with a new rabbit modelResearch to improve our understanding of...
-
Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a s...
